Inaktiver Wert

Andere Sprachen Neuralstem, Inc. Nyse

Aktien

US64127R3021

Schlusskurs Nyse Andere Börsenplätze
- ^USD	-

07.05.	Palisade Bio, Inc. ernennt Margery Fischbein zum Mitglied des Verwaltungsrats	CI
01.05.	Wall Street eröffnet vor der Zinsentscheidung der Fed niedriger; private Beschäftigungszahlen übertreffen Prognosen	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update	14.05.
Palisade Bio, Inc. announced that it has received $3.999943 million in funding	10.05.
Palisade Bio Appoints Margery Fischbein to its Board of Directors	07.05.
Palisade Bio, Inc. Appoints Margery Fischbein to Its Board of Directors	07.05.
Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules	02.05.
Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts	01.05.
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)	01.05.
Palisade Bio?s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide	01.05.
Palisade Bio, Inc. announced that it expects to receive $3.999996 million in funding	01.05.
Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach	24.04.
Palisade Bio Collaborating With Strand Life Sciences on Ulcerative Colitis Therapy	23.04.
Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach	23.04.
Palisade Bio, Inc. Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach	23.04.
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 in Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients Stool	17.04.
Sector Update: Health Care Stocks Edge Up Tuesday Afternoon	16.04.
Palisade Bio Shows Bioactivation of PALI-2108 in Study; Shares Rise	16.04.
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool	16.04.
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients? Stool	16.04.
Palisade Bio to Participate in the Virtual Investor Lunch Break Event	11.04.
Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™	10.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Neuralstem, Inc. Nyse

Aktien

US64127R3021

Andere Sprachen

Filter